Editorial Comment to "Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab".

Saved in:
Bibliographic Details
Title: Editorial Comment to "Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab".
Authors: Hirata H; Department of Urology, Yamaguchi Rosai Hospital, Sanyo-Onoda, Japan.
Source: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2026 Oct; Vol. 33 (10), pp. e70658.
Publication Type: Editorial
Journal Info: Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 9440237 Publication Model: Print Cited Medium: Internet ISSN: 1442-2042 (Electronic) Linking ISSN: 09198172 NLM ISO Abbreviation: Int J Urol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1442-2042
DOI:10.1111/iju.70658